Arecor Therapeutics PLC Arecor on Investor Meet Company Platform
15 Settembre 2023 - 8:00AM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
15 September 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor to present on Investor Meet Company Platform
Cambridge, UK, 15 September 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that Sarah Howell, Chief
Executive Officer and Susan Lowther, Chief Financial Officer will
be providing a live presentation of the Group's recently announced
results for the six months ended 30 June 2023 via the Investor Meet
Company platform, on Wednesday 20 September at 2pm BST.
The presentation is open to all existing and potential
shareholders and will be followed by a Q&A session. Questions
can be submitted ahead of the event through the Investor Meet
Company dashboard until 9am BST on Tuesday 19 September, or at any
time during the live presentation.
To sign up to Investor Meet Company for free and to register for
Arecor's presentation, please visit:
https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor
Investors who already follow Arecor on the Investor Meet Company
platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
. For further details please see our website, www.arecor.com
-
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRALIMLTMTABBAJ
(END) Dow Jones Newswires
September 15, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Set 2023 a Set 2024